Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL319395 | 0.82 | — | — | |
| SCHEMBL3464502 | 0.78 | ITGB3 (0.33) | — | |
| SCHEMBL1581890 | 0.77 | — | — | |
| SCHEMBL661753 | 0.77 | — | — | |
| SCHEMBL20221600 | 0.76 | — | — | |
| SCHEMBL21017064 | 0.76 | MAPT (0.30) | — | |
| SCHEMBL3264014 | 0.76 | TSHR (0.39) | — | |
| SCHEMBL15114370 | 0.76 | — | — | |
| SCHEMBL15116856 | 0.76 | ALDH1A1 (0.34) | — | |
| SCHEMBL13065405 | 0.75 | CHRNB2 (0.32) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3551632-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2024-06-12 | — | — | EP | disclosed |
| US-20220362259-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2022-11-17 | — | — | US | disclosed |
| US-11065257-B2 | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2021-07-20 | — | — | US | disclosed |
| US-11065257-B2 | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2021-07-20 | — | — | US | disclosed |
| EP-3551633-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | disclosed |
| EP-3551633-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | disclosed |
| EP-3475262-B1 | BICYCLIC IMIDAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF RENAL DISEASE, CARDIOVASCULAR DISEASES AND FIBROTIC DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-24 | — | — | EP | disclosed |
| EP-3475262-B1 | BICYCLIC IMIDAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF RENAL DISEASE, CARDIOVASCULAR DISEASES AND FIBROTIC DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2021-03-24 | — | — | EP | disclosed |
| US-10906915-B2 | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2021-02-02 | — | — | US | disclosed |
| US-10906915-B2 | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2021-02-02 | — | — | US | disclosed |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-06-25 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
| US-8084649-B2 | Herbicides | SYNGENTA CROP PROTECTION, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-7943636-B2 | 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-05-17 | — | — | US | disclosed |
| US-20100173774-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| EP-2121584-A2 | NOVEL HERBICIDES | Syngeta Participations AG (CH) | 2009-11-25 | — | — | EP | disclosed |
| US-20090163533-A1 | 1-Substituted Pyrazolo (3,4-C) Ring Compounds as Modulators of Cytokine Biosynthesis for the Treatment of Viral Infections and Neoplastic Diseases | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| WO-2008110308-A2 | NOVEL HERBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-09-18 | — | — | WO | disclosed |
| EP-1863814-A1 | 1-SUBSTITUTED PYRAZOLO (3,4-C) RING COMPOUNDS AS MODULATORS OF CYTOKINE BIOSYNTHESIS FOR THE TREATMENT OF VIRAL INFECTIONS AND NEOPLASTIC DISEASES | Coley Pharmaceutical Group, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006107851-A1 | 1-SUBSTITUTED PYRAZOLO (3,4-C) RING COMPOUNDS AS MODULATORS OF CYTOKINE BIOSYNTHESIS FOR THE TREATMENT OF VIRAL INFECTIONS AND NEOPLASTIC DISEASES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906915-B2 | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | PDE4A, PDE4B, PDE12 | SMN1; SMN2 4348/4885GAA 1556/4885CHRNB2 1734/4885 |
| US-20220362259-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE12 | SMN1; SMN2 4348/4885GAA 1556/4885CHRNB2 1734/4885 |
| US-20150175541-A1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | EGLN2, EGLN3, EGLN1 | SMN1; SMN2 2832/4885GAA 3814/4885CHRNB2 4204/4885 |
| US-11065257-B2 | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | PDE4A, PDE4B, PDE12 | SMN1; SMN2 4348/4885GAA 1556/4885CHRNB2 1734/4885 |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | SMN1; SMN2 4705/4885GAA 931/4885CHRNB2 4868/4885 |
| US-20100173774-A1 | NOVEL HERBICIDES | DDT, HDHD5, HPD | SMN1; SMN2 4024/4885GAA 1281/4885CHRNB2 1957/4885 |
| US-20090163533-A1 | 1-Substituted Pyrazolo (3,4-C) Ring Compounds as Modulators of Cytokine Biosynthesis for the Treatment of Viral Infections and Neoplastic Diseases | IL2, IL4, IFNG | SMN1; SMN2 4525/4885GAA 2310/4885CHRNB2 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.